Patents by Inventor Roger S. Newton

Roger S. Newton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220145309
    Abstract: Various recombinant yeast suitable for use in oral vaccination, vaccine compositions, food compositions, methods of vaccinating an animal, and related methods, kits, and nucleic acid molecules are described.
    Type: Application
    Filed: May 21, 2020
    Publication date: May 12, 2022
    Inventors: David James O'Hagan, Savita Sunil Nikam, Roger S. Newton
  • Publication number: 20170209402
    Abstract: The invention provides methods of using carboxy-cyclopropyl undecanol compounds and pharmaceutically acceptable salts thereof to treat liver disease and other medical disorders associated with elevated lipid levels in the liver. Exemplary carboxy-cyclopropyl undecanol compounds described herein include 1,11-bis-(1-carboxy-cyclopropyl)-undecan-6-ol and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 20, 2015
    Publication date: July 27, 2017
    Inventors: Jeffrey C. Hanselman, Rai Ajit K. Srivastava, Roger S. Newton
  • Patent number: 9610324
    Abstract: The present invention provides a pharmaceutical composition comprising a mixture of apolipoproteins. Methods for elevating HDL levels are also provided as are methods for the treatment and prevention of cardiovascular diseases and disorders, inflammation and metabolic diseases.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: April 4, 2017
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Stephen L. Pinkosky, Sergey V. Filippov, Timothy R. Hurley, Rai Ajit K. Srivastava, Roger S. Newton
  • Publication number: 20150150939
    Abstract: The present invention provides a pharmaceutical composition comprising a mixture of apolipoproteins. Methods for elevating HDL levels are also provided as are methods for the treatment and prevention of cardiovascular diseases and disorders, inflammation and metabolic diseases.
    Type: Application
    Filed: July 11, 2013
    Publication date: June 4, 2015
    Inventors: Stephen L. Pinkosky, Sergey V. Filippov, Timothy R. Hurley, Rai Ajit K. Srivastava, Roger S. Newton
  • Publication number: 20130137628
    Abstract: An isolated oxidation-resistant ApoA1 variant dimer includes a first oxidation-resistant ApoA1 variant polypeptide monomer and a second oxidation-resistant ApoA1 variant polypeptide monomer, wherein at least one of the first and the second monomers comprises at least one amino acid substitution of a tryptophan residue for an oxidation resistant amino acid, or a functional fragment or variant thereof. Methods for treating a disease or disorder comprises administering to a subject in need thereof, a therapeutically effective amount of an isolated oxidation-resistant ApoA1 variant dimer, an oxidation-resistant ApoA1 variant monomer, an oxidation-resistant ApoA1 monomer-lipid complex, a lipid complexed oxidation-resistant ApoA1 variant monomer, a lipid complexed oxidation-resistant ApoA1 variant dimer, or combinations thereof to the subject to enhance cholesterol efflux activity in the presence of an oxidant.
    Type: Application
    Filed: May 11, 2011
    Publication date: May 30, 2013
    Applicant: ESPERION THERAPEUTICS, INC.
    Inventors: Roger S. Newton, Rai Ajit K. Srivastava, Timothy R. Hurley, Clay Cramer, Sergey V. Filippov, Stephen L. Pinkosky
  • Patent number: 6974702
    Abstract: The present invention relates to methods for high information content (HIC) analysis or screening of complex biological systems using Fourier transform mass spectrometry (FTMS). The present methods are useful for analyzing complex biological mixtures containing both high molecular weight molecules (e.g., polynucleotides, proteins, polysaccharides) and low molecular weight molecules (e.g., oligonucleotides, peptides, lipids, oligosaccharides, steroid hormones, catabolic and metabolic intermediates) permit the elucidation of molecular differences between complex biological samples, and permit the identification of biologically active molecules (e.g. therapeutically active drugs, etc.).
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: December 13, 2005
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis H. Dasseux, Roger S. Newton, Thomas J. Rea, Charles L. Bisgaier, Michael E. Pape
  • Patent number: 6680203
    Abstract: The present invention relates to methods for high information content (HIC) analysis or screening of complex biological systems using Fourier transform mass spectrometry (FTMS). The present methods are useful for analyzing complex biological mixtures containing both high molecular weight molecules (e.g., polynucleotides, proteins, polysaccharides) and low molecular weight molecules (e.g., oligonucleotides, peptides, lipids, oligosaccharides, steroid hormones, catabolic and metabolic intermediates) permit the elucidation of molecular differences between complex biological samples, and permit the identification of biologically active molecules (e.g. therapeutically active drugs, etc.).
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: January 20, 2004
    Assignee: Esperion Therapeutics, Inc.
    Inventors: Jean-Louis H. Dasseux, Roger S. Newton, Thomas J. Rea, Charles L. Bisgaier, Michael E. Pape
  • Publication number: 20020019023
    Abstract: The present invention relates to methods for high information content (HIC) analysis or screening of complex biological systems using Fourier transform mass spectrometry (FTMS). The present methods are useful for analyzing complex biological mixtures containing both high molecular weight molecules (e.g., polynucleotides, proteins, polysaccharides) and low molecular weight molecules (e.g., oligonucleotides, peptides, lipids, oligosaccharides, steroid hormones, catabolic and metabolic intermediates) permit the elucidation of molecular differences between complex biological samples, and permit the identification of biologically active molecules (e.g. therapeutically active drugs, etc.).
    Type: Application
    Filed: December 12, 2000
    Publication date: February 14, 2002
    Inventors: Jean-Louis H. Dasseux, Roger S. Newton, Thomas J. Rea, Charles L. Bisgaier, Michael E. Pape
  • Publication number: 20010028895
    Abstract: Blood cholesterol levels are correlated with production of amyloid &bgr; protein (A&bgr;), and are predictors of populations at risk of developing AD. Methods for increasing HDL-cholesterol levels, HDL-apoA-I levels, or HDL function, can be used to decrease production of A&bgr;, thereby decreasing the risk of developing AD. Compounds which function as HDL include synthetic HDL which contains lipid such as phosphotidyl choline, phosphatidyl serine, phosphatidyl ethanolamine, and other phospholipids. Compounds which enhance HDL function include HDL associated proteins such as apo A1 or variants thereof including apo AI-Milano and biologically active peptides derived therefrom, reverse lipid transport (RLT) peptides, apoE, enzymes associated with HDL such as paraoxonase, and LCAT, alone or, more preferably, formulated in combination with liposomes or emulsions.
    Type: Application
    Filed: February 2, 2001
    Publication date: October 11, 2001
    Inventors: Charles L. Bisgaier, Roger S. Newton
  • Patent number: 5877022
    Abstract: Enzymatic RNA molecules which cleave apo(a) mRNA.
    Type: Grant
    Filed: December 26, 1996
    Date of Patent: March 2, 1999
    Assignees: Ribozyme Pharmaceuticals, Inc, Warner Lambert
    Inventors: Dan T. Stinchcomb, James McSwiggen, Roger S. Newton, Randy Ramharack
  • Patent number: 5599706
    Abstract: Enzymatic RNA molecules which cleave apo(a) mRNA.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: February 4, 1997
    Inventors: Dan T. Stinchcomb, James McSwiggen, Roger S. Newton, Randy Ramharack